NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $2.69 -0.02 (-0.74%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$2.66▼$2.7450-Day Range$2.69▼$4.1152-Week Range$2.66▼$8.05Volume1.46 million shsAverage Volume1.49 million shsMarket Capitalization$790.99 millionP/E RatioN/ADividend YieldN/APrice Target$16.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AbCellera Biologics alerts: Email Address AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside501.0% Upside$16.17 Price TargetShort InterestBearish9.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 starsMedical Sector608th out of 879 stocksPharmaceutical Preparations Industry286th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 1 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.55% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 2.1 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AbCellera Biologics this week, compared to 2 articles on an average week.Search InterestOnly 16 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.60) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesJuly 3, 2024 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Sees Large Increase in Short InterestJune 30, 2024 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseJuly 8, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 25, 2024 | businesswire.comAbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024June 13, 2024 | fool.comDown 57%, Is AbCellera Biologics a Buy on the Dip?May 28, 2024 | businesswire.comAbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 16, 2024 | markets.businessinsider.comKeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)May 16, 2024 | seekingalpha.comAbCellera: If You Build It, Will They Come? Fresh Impetus RequiredJuly 8, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 15, 2024 | seekingalpha.comAbCellera: Cash Providing Shelter From Market WeaknessMay 13, 2024 | investorplace.com3 Stock Gems Hiding in the NasdaqMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71May 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising PartnershipsMay 8, 2024 | fool.comAbCellera Biologics (ABCL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comQ1 2024 Abcellera Biologics Inc Earnings CallMay 7, 2024 | investorplace.comABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss EstimatesSee More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/08/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees586Year FoundedN/APrice Target and Rating Average Stock Price Target$16.17 High Stock Price Target$24.00 Low Stock Price Target$7.00 Potential Upside/Downside+501.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-410.47% Pretax Margin-471.19% Return on Equity-12.61% Return on Assets-9.79% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$38.03 million Price / Sales20.80 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.68Miscellaneous Outstanding Shares294,050,000Free Float198,633,000Market Cap$790.99 million OptionableOptionable Beta0.39 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 54)J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Comp: $644.4kMr. Neil Aubuchon B.A. (Age 53)M.B.A., Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Kathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMr. Murray McCutcheon Ph.D.Senior Vice President of PartneringMore ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRCorcept TherapeuticsNASDAQ:CORTMerusNASDAQ:MRUSBiohavenNYSE:BHVNDyne TherapeuticsNASDAQ:DYNView All CompetitorsInstitutional OwnershipWalleye Trading LLCSold 300 shares on 5/17/2024Ownership: 0.000%B. Riley Wealth Advisors Inc.Sold 9,000 shares on 5/16/2024Ownership: 0.004%Baker BROS. Advisors LPBought 4,615,887 shares on 5/15/2024Ownership: 9.361%Lazard Asset Management LLCSold 1,391,993 shares on 5/15/2024Ownership: 0.687%Nan Fung Group Holdings LtdBought 38,450 shares on 5/14/2024Ownership: 0.017%View All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $5.71 at the start of the year. Since then, ABCL shares have decreased by 52.9% and is now trading at $2.69. View the best growth stocks for 2024 here. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The company's quarterly revenue was down 18.4% on a year-over-year basis. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.